Related references
Note: Only part of the references are listed.FOXA1 and IRF-1 intermediary transcriptional regulators of PPAR gamma-induced urothelial cytodifferentiation
C. L. Varley et al.
CELL DEATH AND DIFFERENTIATION (2009)
Effects of PPAR agonists on proliferation and differentiation in human urothelium
Claire L. Varley et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2008)
Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
Ronald A. Lubet et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
Gerald G. Long et al.
TOXICOLOGIC PATHOLOGY (2008)
Urinary glycosaminoglycans as biomarker for urothelial injury: Is it possible to discriminate damage from recovery?
Roberto Soler et al.
UROLOGY (2008)
Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium
William E. Achanzar et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2007)
Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar
Sarah H. Tannehill-Gregg et al.
TOXICOLOGICAL SCIENCES (2007)
Investigations of rodent urinary bladder carcinogens: Collection, processing, and evaluation of urine and bladders
Samuel M. Cohen et al.
TOXICOLOGIC PATHOLOGY (2007)
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action
Mark A. Dominick et al.
TOXICOLOGIC PATHOLOGY (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo
FL Egerod et al.
BIOMARKERS (2005)
Role of PPARγ and EGFR signalling in the urothelial terminal differentiation programme
CL Varley et al.
JOURNAL OF CELL SCIENCE (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peroxisome-proliferator-activated receptors and cancers: Complex stories
L Michalik et al.
NATURE REVIEWS CANCER (2004)
Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone
JR Herman et al.
TOXICOLOGICAL SCIENCES (2002)
Share Paper
